{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"DoR was defined as the time from the date measurement criteria for CR or PR (whichever is first recorded) are first met until the first date that disease is recurrent or objective progression is observed, per RECIST v1.1 criteria, or the date of death from any cause in the absence of objectively determined disease progression or recurrence.","groups":[{"description":"Participants received high dose LY3499446 as oral monotherapy BID in 21-day cycles.","id":"OG000","title":"LY3499446 Phase 1 Cohort A1 (High Dose)"},{"description":"Participant received mid dose LY3499446 as oral monotherapy once QOD in 21-day cycles.","id":"OG001","title":"LY3499446 Phase 1 Cohort AO (Mid Dose)"},{"description":"Participants received low dose LY3499446 as oral monotherapy once QD in 21-day cycles.","id":"OG002","title":"LY3499446 Phase 1 Cohort A-2 (Low Dose)"}],"populationDescription":"Zero participants were analyzed due to early termination of study.","reportingStatus":"POSTED","timeFrame":"Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 11 Months)","title":"Phase 1: Duration of Response (DoR)","type":"SECONDARY"}